The Street is underestimating Johnson & Johnson (JNJ), Citi's Matthew Dodds maintains, and...

|About: Johnson & Johnson (JNJ)|By:, SA News Editor

The Street is underestimating Johnson & Johnson (JNJ), Citi's Matthew Dodds maintains, and shares could pop if sales exceed estimates when it reports its Q1 tomorrow morning: "All three of JNJ’s divisions are expected to see accelerating sales growth as we move through 2012, with a notable jump set for Q3 when generic pharma comparisons ease."